Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo

被引:30
作者
Bowman, Karen J. [1 ]
Al-Moneef, Manar M. [1 ]
Sherwood, Benedict T. [1 ,2 ]
Colquhoun, Alexandra J. [1 ,2 ]
Goddard, Jonathan C. [1 ,2 ]
Griffiths, T. R. Leyshon [1 ,2 ]
Payne, David [1 ,2 ]
Singh, Sadmeet [2 ]
Butterworth, Paul C. [2 ]
Khan, Masood A. [2 ]
Summerton, Duncan J. [2 ]
Steward, William P. [1 ]
McKelvey-Martin, Valerie J. [3 ]
McKeown, Stephanie R. [3 ]
Kockelbergh, Roger C. [2 ]
Mellon, J. Kilian [1 ,2 ]
Symonds, R. Paul [1 ]
Jones, George D. D. [1 ]
机构
[1] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE2 7LX, Leics, England
[2] Univ Hosp Leicester NHS Trust, Dept Urol, Leicester, Leics, England
[3] Univ Ulster, Biomed Sci Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland
关键词
bladder cancer; DNA damage; Comet assay; treatment; cell sensitivity; recurrence; INTRAVESICAL MITOMYCIN-C; RADICAL RADIOTHERAPY; IONIZING-RADIATION; METASTATIC CANCER; INDIVIDUAL CELLS; TUMOR RESPONSE; POTENTIAL USE; REPAIR GENES; CISPLATIN; CARCINOMA;
D O I
10.1002/ijc.28437
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Bladder cancer patients suffer significant treatment failure, including high rates of recurrence and poor outcomes for advanced disease. If mechanisms to improve tumour cell treatment sensitivity could be identified and/or if tumour response could be predicted, it should be possible to improve local-control and survival. Previously, we have shown that radiation-induced DNA damage, measured by alkaline Comet assay (ACA), correlates bladder cancer cell radiosensitivity in vitro. In this study we first show that modified-ACA measures of cisplatin and mitomycin-C-induced damage also correlate bladder cancer cell chemosensitivity in vitro, with essentially the same rank order for chemosensitivity as for radiosensitivity. Furthermore, ACA studies of radiation-induced damage in different cell-DNA substrates (nuclei, nucleoids and intact parent cells) suggest that it is a feature retained in the prepared nucleoids that is responsible for the relative damage sensitivity of bladder cancer cells, suggestive of differences in the organisation of DNA within resistant vs. sensitive cells. Second, we show that ACA analysis of biopsies from bladder tumours reveal that reduced DNA damage sensitivity associates with poorer treatment outcomes, notably that tumours with a reduced damage response show a significant association with local recurrence of non-invasive disease and that reduced damage response was a better predictor of recurrence than the presence of high-risk histology in this cohort. In conclusion, this study demonstrates that mechanisms governing treatment-induced DNA damage are both central to and predictive of bladder cancer cell treatment sensitivity and exemplifies a link between DNA damage resistance and both treatment response and tumour aggression.
引用
收藏
页码:1102 / 1111
页数:10
相关论文
共 52 条
[1]
Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: Implications for predictive testing [J].
Almeida, Gabriela M. ;
Duarte, Tiago L. ;
Farmer, Peter B. ;
Steward, William P. ;
Jones, George D. D. .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (08) :1810-1819
[2]
The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy [J].
Aparicio, AM ;
Elkhouiery, AB ;
Quinn, DI .
UROLOGIC CLINICS OF NORTH AMERICA, 2005, 32 (02) :217-+
[3]
Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours:: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy [J].
Basu, S ;
Brown, JE ;
Flannigan, GM ;
Gill, JH ;
Loadman, PM ;
Martin, SW ;
Naylor, B ;
Scally, AJ ;
Seargent, JM ;
Shah, T ;
Puri, R ;
Phillips, RM .
INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (05) :703-709
[4]
Biomarkers in bladder cancer [J].
Bryan, Richard T. ;
Zeegers, Maurice P. ;
James, Nicholas D. ;
Wallace, D. Michael A. ;
Cheng, Kar Keung .
BJU INTERNATIONAL, 2010, 105 (05) :608-613
[5]
Carther SK CS, 1979, MITOMYCIN C CURRENT
[6]
Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer [J].
Choudhury, Ananya ;
Swindell, Ric ;
Logue, John P. ;
Elliott, P. Anthony ;
Livsey, Jacqueline E. ;
Wise, Marcus ;
Symonds, Paul ;
Wylie, James P. ;
Ramani, Vijay ;
Sangar, Vijay ;
Lyons, Jeanette ;
Bottomley, Ian ;
McCaul, Damian ;
Clarke, Noel W. ;
Kiltie, Anne E. ;
Cowan, Richard A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) :733-738
[7]
MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer [J].
Choudhury, Ananya ;
Nelson, Louisa D. ;
Teo, Mark T. W. ;
Chilka, Sameer ;
Bhattarai, Selina ;
Johnston, Colin F. ;
Elliott, Faye ;
Lowery, Johanna ;
Taylor, Claire F. ;
Churchman, Michael ;
Bentley, Johanne ;
Knowles, Margaret A. ;
Harnden, Patricia ;
Bristow, Robert G. ;
Bishop, D. Timothy ;
Kiltie, Anne E. .
CANCER RESEARCH, 2010, 70 (18) :7017-7026
[8]
The comet assay for DNA damage and repair - Principles, applications, and limitations [J].
Collins, AR .
MOLECULAR BIOTECHNOLOGY, 2004, 26 (03) :249-261
[9]
Improving and predicting radiosensitivity in muscle invasive bladder cancer [J].
Colquhoun, AJ ;
Jones, GDD ;
Al Moneef, M ;
Bowman, KJ ;
Kockelbergh, RC ;
Symonds, RP ;
Steward, WP ;
Mellon, JK .
JOURNAL OF UROLOGY, 2003, 169 (06) :1983-1992
[10]
Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer [J].
Cooke, PW ;
Dunn, JA ;
Latief, T ;
Bathers, S ;
James, ND ;
Wallace, DMA .
EUROPEAN UROLOGY, 2000, 38 (03) :279-285